Metastatic gastrointestinal cancer is not an uncommon situation, especially for pancreatic, gastric, and colorectal cancers. In this setting, few data are available on the impact of the treatment of the primary tumour. Oligometastatic disease is associated with longer survival in comparison with more advanced disease. Metastasis-directed therapy, such as stereotactic body radiotherapy, seems related to better outcomes, but the level of evidence is low. In most tumour locations, prospective data are very scarce and inclusion in ongoing trials is strongly recommended.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.canrad.2023.04.007 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!